Skip to main content
Premium Trial:

Request an Annual Quote

Xceleron, JCL Bioassay Partner on Screening Technologies

NEW YORK (GenomeWeb News) – Xceleron announced today that it will collaborate with JCL Bioassay in offering drug developers access to their respective technologies for drug screening and development applications.

Xceleron said that the partnership will offer clinical design expertise and appropriate analytical platforms for early clinical investigation. It added that between the firms they have developed more than 100 analytical methods for Phase 0 and Phase 1 investigations.

Germantown, Md.-based Xceleron provides bioanalytical services based on accelerator mass spectrometry technology. Hoffman Estates, Ill.-based JCL Bioassay USA, which is part of Japanese CRO JCL Bioassay, provides bioassay services using LC-MS/MS and other methodologies.

The alliance covers Asia, Europe, and North America. Further terms of the agreement were not disclosed.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.